FBXL10 contributes to the development of diffuse large B-cell lymphoma by epigenetically enhancing ERK1/2 signaling pathway
暂无分享,去创建一个
Xudong Wu | Jun-qiang Lv | N. Zhang | Qian Li | Wanbiao Chen | Guogang Xu | Lei Cao | D. Lin | Xing Wang | Xiujuan Zhao | Yu Kong | Xi Wang
[1] O. Elemento,et al. EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. , 2016, Cancer cell.
[2] Jihong Han,et al. JMJD3 promotes survival of diffuse large B-cell lymphoma subtypes via distinct mechanisms , 2016, Oncotarget.
[3] Weiqun Peng,et al. Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis. , 2016, The Journal of clinical investigation.
[4] Steven L Salzberg,et al. HISAT: a fast spliced aligner with low memory requirements , 2015, Nature Methods.
[5] K. Basso,et al. Germinal centres and B cell lymphomagenesis , 2015, Nature Reviews Immunology.
[6] S. Naber,et al. NDY1/KDM2B functions as a master regulator of polycomb complexes and controls self-renewal of breast cancer stem cells. , 2014, Cancer research.
[7] N. Brockdorff,et al. Variant PRC1 Complex-Dependent H2A Ubiquitylation Drives PRC2 Recruitment and Polycomb Domain Formation , 2014, Cell.
[8] Kristian Helin,et al. Chromatin repressive complexes in stem cells, development, and cancer. , 2014, Cell stem cell.
[9] O. Elemento,et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. , 2013, Cancer cell.
[10] C. Tam,et al. High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone? , 2013, Leukemia & lymphoma.
[11] K. Helin,et al. Fbxl10/Kdm2b recruits polycomb repressive complex 1 to CpG islands and regulates H2A ubiquitylation. , 2013, Molecular cell.
[12] Hao Wu,et al. Kdm2b maintains murine embryonic stem cell status by recruiting PRC1 complex to CpG islands of developmental genes , 2013, Nature Cell Biology.
[13] P. Park,et al. KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. , 2013, The Journal of clinical investigation.
[14] C. Ponting,et al. KDM2B links the Polycomb Repressive Complex 1 (PRC1) to recognition of CpG islands , 2012, eLife.
[15] K. Basso,et al. Roles of BCL6 in normal and transformed germinal center B cells , 2012, Immunological reviews.
[16] Eric S. Lander,et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing , 2012, Proceedings of the National Academy of Sciences.
[17] A. Conesa,et al. Differential expression in RNA-seq: a matter of depth. , 2011, Genome research.
[18] Colin N. Dewey,et al. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.
[19] L. Gordon,et al. The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. , 2011, Blood.
[20] Steven J. M. Jones,et al. Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.
[21] Raul Rabadan,et al. Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.
[22] Q. Zeng,et al. F-box protein 10, an NF-κB-dependent anti-apoptotic protein, regulates TRAIL-induced apoptosis through modulating c-Fos/c-FLIP pathway , 2011, Cell Death and Differentiation.
[23] Jin He,et al. KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. , 2011, Blood.
[24] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[25] C. Allis,et al. Covalent histone modifications — miswritten, misinterpreted and mis-erased in human cancers , 2010, Nature Reviews Cancer.
[26] Alexander D. MacKerell,et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. , 2010, Cancer cell.
[27] Kristian Helin,et al. Polycomb group proteins: navigators of lineage pathways led astray in cancer , 2009, Nature Reviews Cancer.
[28] Y. Natkunam,et al. Extracellular signal-regulated kinase positively regulates the oncogenic activity of MCT-1 in diffuse large B-cell lymphoma. , 2009, Cancer research.
[29] Robert E. Kingston,et al. Mechanisms of Polycomb gene silencing: knowns and unknowns , 2009, Nature Reviews Molecular Cell Biology.
[30] E. Kandel,et al. Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFκB , 2009, Proceedings of the National Academy of Sciences.
[31] Kenny Q. Ye,et al. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. , 2009, Blood.
[32] L. Cantley,et al. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.
[33] Jürg Müller,et al. Biochemical mechanisms of gene regulation by polycomb group protein complexes. , 2009, Current opinion in genetics & development.
[34] S. Cook,et al. Tumour cell survival signalling by the ERK1/2 pathway , 2009, Cell Death and Differentiation.
[35] J. Molkentin,et al. DUSP6 (MKP3) Null Mice Show Enhanced ERK1/2 Phosphorylation at Baseline and Increased Myocyte Proliferation in the Heart Affecting Disease Susceptibility* , 2008, Journal of Biological Chemistry.
[36] Y. Tsukada,et al. The H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15Ink4b , 2008, Nature Structural &Molecular Biology.
[37] T. Furukawa,et al. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. , 2008, Carcinogenesis.
[38] L. Staudt,et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma , 2007, Leukemia.
[39] J. Armitage. How I treat patients with diffuse large B-cell lymphoma. , 2007, Blood.
[40] C. Sánchez,et al. Proteomics Analysis of Ring1B/Rnf2 Interactors Identifies a Novel Complex with the Fbxl10/Jhdm1B Histone Demethylase and the Bcl6 Interacting Corepressor*S , 2007, Molecular & Cellular Proteomics.
[41] J. A. Wamstad,et al. Polycomb Group and SCF Ubiquitin Ligases Are Found in a Novel BCOR Complex That Is Recruited to BCL6 Targets , 2006, Molecular and Cellular Biology.
[42] L. Platanias. Map kinase signaling pathways and hematologic malignancies. , 2003, Blood.
[43] F. Motoi,et al. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. , 2003, The American journal of pathology.
[44] Mark W. Budwig,et al. A Matter of Depth , 2003 .
[45] E. Verdin,et al. BCoR, a novel corepressor involved in BCL-6 repression. , 2000, Genes & development.
[46] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[47] E. Zabarovsky,et al. Tumor suppressor dual‐specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial‐mesenchymal transition (EMT)‐associated phenotype , 2012, International journal of cancer.
[48] G. Collins. The next generation. , 2006, Scientific American.
[49] G. Davies,et al. Knowns and Unknowns , 2003 .